Computational analysis of expectile and deviation expectile portfolio optimization models

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-07-02 DOI:10.1007/s11081-024-09900-9
Shalu, Amita Sharma, Ruchika Sehgal
{"title":"Computational analysis of expectile and deviation expectile portfolio optimization models","authors":"Shalu, Amita Sharma, Ruchika Sehgal","doi":"10.1007/s11081-024-09900-9","DOIUrl":null,"url":null,"abstract":"<p>Expectile has recently gained an admiration in the area of portfolio optimization (PO) mainly because of its unique property of being both coherent and elicitable function. Additionally, a PO model minimizing Expectile function as risk measure is a linear program under discrete time setting. With these favorable features, we aim to study and analyze the Expectile and its deviation counterpart, deviation Expectile (DExpectile) based PO models in comparison to much more popular PO models comprising Conditional Value-at-Risk (CVaR) and deviation CVaR (DCVaR). We first conduct sensitivity analysis of Expectile and DExpectile PO models with respect to their two model parameters, risk-return trade-off parameter and tail-risk trade-off parameter. Thereafter, we conduct a computational analysis among Expectile, DExpectile, CVaR, and DCVaR PO models on the basis of several performance indices. Empirical study of this paper is carried out over the sample data of S &amp;P 500 (USA) with a sample period from 06 January 2015 to 07 June 2022. Numerical results show the favorable outcomes of Expectile PO model in comparison to the models DExpectile and DCVaR, whereas it performs better than CVaR model for many likely scenarios of model parameters. On many occasions, the model DExpectile dominates DCVaR in terms of mean return, risk measures, and financial ratios while it able to outperform model CVaR under some special cases of parameters. Therefore, our numerical findings hint that the Expectile based PO models can become potential competitors to CVaR based PO models in practice.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s11081-024-09900-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Expectile has recently gained an admiration in the area of portfolio optimization (PO) mainly because of its unique property of being both coherent and elicitable function. Additionally, a PO model minimizing Expectile function as risk measure is a linear program under discrete time setting. With these favorable features, we aim to study and analyze the Expectile and its deviation counterpart, deviation Expectile (DExpectile) based PO models in comparison to much more popular PO models comprising Conditional Value-at-Risk (CVaR) and deviation CVaR (DCVaR). We first conduct sensitivity analysis of Expectile and DExpectile PO models with respect to their two model parameters, risk-return trade-off parameter and tail-risk trade-off parameter. Thereafter, we conduct a computational analysis among Expectile, DExpectile, CVaR, and DCVaR PO models on the basis of several performance indices. Empirical study of this paper is carried out over the sample data of S &P 500 (USA) with a sample period from 06 January 2015 to 07 June 2022. Numerical results show the favorable outcomes of Expectile PO model in comparison to the models DExpectile and DCVaR, whereas it performs better than CVaR model for many likely scenarios of model parameters. On many occasions, the model DExpectile dominates DCVaR in terms of mean return, risk measures, and financial ratios while it able to outperform model CVaR under some special cases of parameters. Therefore, our numerical findings hint that the Expectile based PO models can become potential competitors to CVaR based PO models in practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预期和偏差预期投资组合优化模型的计算分析
Expectile函数最近在投资组合优化(PO)领域备受推崇,这主要是因为它具有既连贯又可激发的独特性质。此外,将 Expectile 函数作为风险度量最小化的投资组合模型是离散时间设置下的线性程序。基于这些有利特征,我们旨在研究和分析基于 Expectile 及其偏差的对应模型--偏差 Expectile (DExpectile) 的 PO 模型,并将其与更流行的 PO 模型(包括条件风险值 (CVaR) 和偏差 CVaR (DCVaR))进行比较。我们首先对 Expectile 和 DExpectile PO 模型的两个模型参数(风险收益权衡参数和尾部风险权衡参数)进行敏感性分析。之后,我们根据几个性能指标对 Expectile、DExpectile、CVaR 和 DCVaR PO 模型进行了计算分析。本文对 S &P 500(美国)的样本数据进行了实证研究,样本期为 2015 年 1 月 6 日至 2022 年 6 月 7 日。数值结果表明,Expectile PO 模型与 DExpectile 和 DCVaR 模型相比结果更佳,而在模型参数的多种可能情况下,Expectile PO 模型的表现优于 CVaR 模型。在许多情况下,Dexpectile 模型在平均收益、风险度量和财务比率方面都优于 DCVaR 模型,而在某些参数的特殊情况下,它的表现也优于 CVaR 模型。因此,我们的数值研究结果表明,基于 Expectile 的 PO 模型在实践中可以成为基于 CVaR 的 PO 模型的潜在竞争对手。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1